Tivity Health Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tivity Health in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tivity Health stock.
View analyst ratings for Tivity Health or view top-rated stocks.

Wall Street analysts have given Tivity Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tivity Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tivity Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Tivity Health.

Tivity Health, Inc. (NASDAQ:TVTY) issued its quarterly earnings data on Wednesday, May, 5th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. The company earned $108.09 million during the quarter, compared to the consensus estimate of $98.67 million. Tivity Health had a positive trailing twelve-month return on equity of 649.58% and a negative net margin of 0.88%.
View Tivity Health's earnings history.

Tivity Health's stock was trading at $7.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TVTY stock has increased by 246.8% and is now trading at $27.40.
View which stocks have been most impacted by COVID-19.

Tivity Health issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of 1.490-1.560 for the period, compared to the Thomson Reuters consensus estimate of $1.520. The company issued revenue guidance of $465 million-$485 million, compared to the consensus revenue estimate of $470.62 million.

7 brokers have issued 12-month price targets for Tivity Health's stock. Their forecasts range from $20.00 to $36.00. On average, they anticipate Tivity Health's share price to reach $25.29 in the next year. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Tivity Health or view top-rated stocks among Wall Street analysts.

8 employees have rated Tivity Health CEO Richard Ashworth on Glassdoor.com. Richard Ashworth has an approval rating of 36% among Tivity Health's employees. This puts Richard Ashworth in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Tivity Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), R1 RCM (RCM), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL) and Cross Country Healthcare (CCRN).
View all of TVTY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tivity Health investors own include NVIDIA (NVDA), Energy Transfer (ET), Pfizer (PFE), Advanced Micro Devices (AMD), AT&T (T), (CGC), Sorrento Therapeutics (SRNE), Applied Materials (AMAT), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Tivity Health trades on the NASDAQ under the ticker symbol "TVTY."

Tivity Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.41%), Goldman Sachs Group Inc. (4.49%), Morgan Stanley (3.05%), The Manufacturers Life Insurance Company (1.70%), Assenagon Asset Management S.A. (1.46%) and Geode Capital Management LLC (1.38%). Company insiders that own Tivity Health stock include Kevin Wills, Lee Shapiro and Sara Finley.
View institutional ownership trends for Tivity Health.

TVTY stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dendur Capital LP, JPMorgan Chase & Co., Morgan Stanley, Millennium Management LLC, Prudential Financial Inc., Atom Investors LP, and Hussman Strategic Advisors Inc..
View insider buying and selling activity for Tivity Health or view top insider-selling stocks.

TVTY stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Point72 Asset Management L.P., BlackRock Inc., Schroder Investment Management Group, D. E. Shaw & Co. Inc., Canada Pension Plan Investment Board, Healthcare of Ontario Pension Plan Trust Fund, and Dimensional Fund Advisors LP. Company insiders that have bought Tivity Health stock in the last two years include Kevin Wills, Lee Shapiro, and Sara Finley.
View insider buying and selling activity for Tivity Health or or view top insider-buying stocks.

Shares of TVTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TVTY stock can currently be purchased for approximately $27.40.

Tivity Health has a market capitalization of $1.35 billion and generates $437.71 million in revenue each year. The company earns $-223,630,000.00 in net income (profit) each year or $1.46 on an earnings per share basis.

Tivity Health employs 350 workers across the globe.

Tivity Health was founded in 2017.

The official website for Tivity Health is www.tivityhealth.com.

Tivity Health is headquartered at 701 Cool Springs Boulevard, Franklin TN, 37067.

Tivity Health's mailing address is 701 Cool Springs Boulevard, Franklin TN, 37067. The company can be reached via phone at 800-869-5311 or via email at [email protected]